Chemotherapy-Induced Neutropenia
Understanding Chemotherapy-Induced Neutropenia: This resource provides essential information for healthcare professionals on the diagnosis, documentation, and medical coding of Chemotherapy-Induced Neutropenia (CIN), also known as Febrile Neutropenia or Neutropenia secondary to chemotherapy. Learn about CIN risk factors, clinical manifestations, and appropriate ICD-10 codes for accurate clinical documentation and billing. This guide supports healthcare providers in optimizing patient care for those experiencing chemo-induced neutropenia.
Low neutrophil count caused by chemotherapy, increasing infection risk.
Fever, chills, weakness, mouth sores, frequent infections.
Oncology clinics, hospitals (inpatient and outpatient).
ICD-10 Code Families
Complete code families applicable to D70.1
When to use each related code
| Description | When to use |
|---|---|
| Low neutrophil count due to chemotherapy | Use when neutropenia is a direct result of chemotherapy treatment. Consider severity and complications. |
| Fever with low neutrophil count after chemotherapy | Use when fever occurs alongside chemotherapy-induced neutropenia, indicating possible infection. |
| Low neutrophil count not caused by chemotherapy | Use when neutropenia is present but NOT related to chemotherapy. Specify the underlying cause. |
Best-practice checklist
- ✓Document absolute neutrophil count (ANC).
- ✓Specify chemotherapy regimen causing neutropenia.
- ✓Record onset and duration of neutropenia.
- ✓Document signs/symptoms (fever, infection).
- ✓Assess and document risk factors for complications.
Common pitfalls to avoid
Coding neutropenia without specifying chemotherapy-induced cause can lead to inaccurate DRG assignment and reimbursement.
Incorrectly coding febrile neutropenia as the primary diagnosis when it's a manifestation of chemotherapy-induced neutropenia can cause coding errors.
Lack of clear documentation linking neutropenia to chemotherapy in the patient's record can cause claim denials and compliance issues.
Best-practice tips
- 01Prophylactic G-CSF for high-risk patients (NCI risk >20%)
- 02Monitor ANC closely, especially during nadir
- 03Patient education on infection prevention measures
- 04Promptly evaluate and treat fever (ANC <500/mm3)
- 05Consider antimicrobial prophylaxis in select cases
Step-by-step checklist
- 1
Verify absolute neutrophil count (ANC) < 1500/mm3 or <1000/mm3 with predicted decline.
- 2
Confirm recent chemotherapy administration within past 2 weeks.
- 3
Assess for signs and symptoms of infection (fever, chills, hypotension).
- 4
Evaluate risk factors: age, comorbidities, prior episodes of neutropenia.
- 5
Review medication list for contributing drugs, consider dose adjustments.
Ready-to-paste narrative
Patient presents with chemotherapy-induced neutropenia, confirmed by absolute neutrophil count (ANC) below 1500 cells/mm3 following recent chemotherapy administration for [Specify underlying malignancy, e.g., breast cancer, lung cancer]. The patient's current ANC is [Insert value] cells/mm3. Symptoms include [List present symptoms, e.g., fever, chills, fatigue, mouth sores, signs of infection]. Patient's temperature is [Insert temperature]. Given the neutropenia and [Presence or absence of fever, specifying temperature if present], the patient meets the criteria for [Specify: febrile neutropenia or low-risk neutropenia]. Differential diagnosis includes drug-induced neutropenia, bone marrow suppression, and infection-related neutropenia. Plan includes complete blood count (CBC) monitoring, blood cultures if febrile, initiation of prophylactic or therapeutic antibiotics as indicated by clinical presentation and risk stratification, growth factor support with granulocyte colony-stimulating factor (G-CSF) consideration, and close monitoring for signs and symptoms of infection. Patient education provided regarding neutropenic precautions, including hand hygiene, infection prevention strategies, and when to seek immediate medical attention. ICD-10 code D70.1, Chemotherapy-induced neutropenia, is applied. This diagnosis impacts medical billing and coding for appropriate reimbursement. Treatment plan aligns with current clinical practice guidelines for the management of chemotherapy-induced neutropenia and febrile neutropenia.
Common questions and answers
What are the evidence-based best practices for managing chemotherapy-induced neutropenia in adult oncology patients?+
Managing chemotherapy-induced neutropenia requires a multifaceted approach focusing on prevention, early detection, and prompt treatment. Evidence-based best practices include prophylactic use of granulocyte colony-stimulating factors (G-CSFs) in high-risk patients receiving myelosuppressive chemotherapy regimens, as outlined in guidelines like the NCCN and ASCO. Regular monitoring of absolute neutrophil counts (ANC) is crucial, especially during the first cycle of chemotherapy. For patients who develop febrile neutropenia (FN), prompt initiation of empiric broad-spectrum antibiotics is essential to minimize the risk of serious complications. Consider implementing risk stratification tools to identify patients at highest risk of FN and tailor management accordingly. Explore how integrating clinical decision support systems can improve adherence to best practices and optimize patient outcomes. Learn more about specific antibiotic recommendations and dosage adjustments for different patient populations.
How can I differentiate between chemotherapy-induced neutropenia and other causes of neutropenia in my clinical practice?+
Distinguishing chemotherapy-induced neutropenia from other etiologies necessitates a thorough patient history, including medication review, recent infections, and underlying medical conditions. Chemotherapy is a common and often expected cause of neutropenia, particularly with myelosuppressive regimens. However, other causes like autoimmune disorders, bone marrow infiltration by malignancy, or certain medications can also lead to neutropenia. Key differentiating factors include the temporal relationship between chemotherapy administration and the onset of neutropenia, the patient's overall clinical picture, and the presence of other cytopenias. Bone marrow biopsy may be indicated in cases where the etiology remains unclear. Consider implementing a diagnostic algorithm to systematically evaluate neutropenia and identify the underlying cause. Explore the latest research on genetic predispositions to neutropenia and their implications for chemotherapy dosing and supportive care.
What are the most effective strategies for preventing febrile neutropenia in patients undergoing chemotherapy for solid tumors?+
Preventing febrile neutropenia in patients undergoing chemotherapy for solid tumors hinges on minimizing the duration and severity of neutropenia. Primary prophylaxis with G-CSFs is a cornerstone of preventative strategies, especially in patients receiving highly myelosuppressive chemotherapy or those with additional risk factors such as age, comorbidities, or prior episodes of FN. Dose-dense chemotherapy regimens, while offering potential benefits in terms of tumor response, can increase the risk of FN and may require even more stringent preventative measures. Patient education regarding infection prevention practices, including hand hygiene, avoidance of sick contacts, and prompt reporting of fever, is also essential. Learn more about optimizing chemotherapy dosing and scheduling to minimize neutropenia while maintaining treatment efficacy. Explore how advancements in supportive care, such as novel G-CSF formulations and biosimilar options, can further enhance FN prevention strategies.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.